Virtu Financial LLC Acquires New Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Virtu Financial LLC bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,266 shares of the biotechnology company's stock, valued at approximately $381,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ARWR. HighTower Advisors LLC raised its position in Arrowhead Pharmaceuticals by 11.5% during the 3rd quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company's stock worth $2,401,000 after buying an additional 12,706 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $659,000. Erste Asset Management GmbH purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $924,000. Geode Capital Management LLC lifted its position in Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after purchasing an additional 26,171 shares during the period. Finally, State Street Corp raised its stake in shares of Arrowhead Pharmaceuticals by 8.8% during the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock valued at $123,083,000 after buying an additional 516,569 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Up 0.1 %

Arrowhead Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $13.82. The company had a trading volume of 974,317 shares, compared to its average volume of 1,338,889. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -2.67 and a beta of 0.92. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $13.66 and a 1 year high of $30.41. The business has a fifty day moving average of $18.13 and a 200 day moving average of $19.61.

Remove Ads

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). On average, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kenneth Allen Myszkowski sold 27,167 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.83, for a total transaction of $538,721.61. Following the completion of the sale, the chief financial officer now owns 473,433 shares of the company's stock, valued at approximately $9,388,176.39. This trade represents a 5.43 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 286,317 shares of company stock worth $5,049,735. Corporate insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ARWR shares. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. B. Riley reissued a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $41.44.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.